Clinical trial Recruiting at 1 site Observational Ages 50 to 70 Women only

Effects of cancer treatments on metabolism and bone health in early breast cancer survivors

Official title: Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.

Run by Copenhagen University Hospital, Rigshospitalet · NCT03784651 · Data updated 2026-11-12

This study is testing how cancer treatments affect metabolism and bone health in post-menopausal women aged 50-70 who have survived early breast cancer.

More Insulin Resistance trials

Quick facts

Study typeObservational
Ages50 Years to 70 Years
SexWomen only
Enrollment120 (estimated)
SponsorCopenhagen University Hospital, Rigshospitalet
Academic / other
Drugs / interventionschemotherapy, Radiation
Locations1 site (Copenhagen, Danmark)
StatusRecruiting
StartedDecember 17, 2018
Main results expectedNovember 2021
Study endsNovember 2026
Registry record updatedSeptember 16, 2021
Trial IDNCT03784651 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are post-menopausal women aged 50-70 who have been diagnosed with early-stage breast cancer and are eligible for (neo-)adjuvant chemotherapy.

Probably not a fit

Patients with prior malignancies or existing metabolic diseases such as diabetes mellitus may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the metabolic and bone health changes in post-menopausal women aged 50-70 who have been treated for early non-metastatic breast cancer. Over a five-year period, the study will assess factors such as bone mineral density, body composition, glucose metabolism, and nerve damage before and after chemotherapy. The goal is to identify the physiological and molecular mechanisms behind treatment-related side effects and to discover potential biomarkers for predicting and preventing metabolic diseases. A questionnaire will also be utilized to gather additional health information from participants.

Why it matters

Potential benefit: If successful, this study could lead to improved strategies for preventing metabolic diseases in breast cancer survivors.

How similar studies have gone: Other studies have shown success in understanding treatment-related side effects in cancer survivors, but this specific focus on metabolic and bone changes is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Postmenopausal
* Breast cancer stage I-III
* Eligible to receive (neo-)adjuvant chemotherapy/other antineoplastic treatment

Exclusion Criteria:

* Prior malignancy
* Metabolic disease (diabetes mellitus etc)

Where it's running

  • Rigshospitalet
    Copenhagen, Danmark, Denmark
    Recruiting

Study contacts

  • Principal investigator: Peter Schwarz, Prof, MD — Copenhagen University Hospital, Rigshospitalet
  • Study coordinator: Kristian Buch, cand.med.
  • Email: buch.kristian@gmail.com
  • Phone: 29434376

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.